Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

47,725 stories, page 43 of 796

Advanced search

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Telcon Rf Pharmaceutical Wins 3.6 Billion Won Order

TradingViewOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Biontech And Dualitybio Announce Topline Results Of Global Phase 3 Clinical Trial for Breast Cancer

TradingViewOriginal source

🇺🇰Oct 26Regulatorygov.ukTier 1 · Regulatory source

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2025 to September 2026

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

UK Health Security AgencyOriginal source

🇩🇪Oct 26Researchklinikum.uni-heidelberg.deTier 2 · Direct publisher

Deeskalationsvisite – Unterstützung, Austausch und Sicherheit im Pflegealltag

Universitätsklinikum HeidelbergOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

BioNTech's drug modestly extended time without cancer progression vs. chemo. A few had severe or fatal lung disease.

Stock TitanOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

Carroll County Mirror-DemocratOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

New Orleans-based biotech company lured to SC as first for MUSC lab

YahooOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Genmab to test drug candidate with US biotech partner

medwatch.comOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

The Enzyme Nobody Watched: How Mitapivat’s Phase 3 Win Rewrites the Rules for Sickle Cell Drug Development

The Clinical Trial VanguardOriginal source

🇸🇪Oct 26Researchvgrfokus.seTier 3 · Secondary coverage

Hitta festivaler året om på ny karta

Sahlgrenska SwedenOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

New lung cancer drug adds nearly six months of survival stomach cancer treatment doubles it

YnetnewsOriginal source

🇩🇪Oct 26pharma_equipmentsyntegon.comTier 2 · Direct publisher

Synexio: the basis for shared success | Syntegon

Syntegon (Bosch Packaging)Original source

🇪🇸Oct 26Regulatoryaemps.gob.esTier 1 · Regulatory source

La AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en septiembre

AEMPS (Spain)Original source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Kelun-Biotech's sac-TMT improves overall survival in final Phase 3 lung cancer analysis

DealroomOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Could new US investment curbs complicate China’s biotech licensing surge?

South China Morning PostOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

China warns of retaliation as US widens biotech investment restrictions

www.tmgm.comOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Pharmacy Students Meet Dozens of Potential Employers at Career Launch Day

UToledo NewsOriginal source

🇯🇵Oct 26Industrychugai-pharm.co.jpTier 1 · Company source

ロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAgINATION試験の中間解析の詳細データ）

Chugai Pharmaceutical NewsOriginal source

🇯🇵Oct 26Industrychugai-pharm.co.jpTier 1 · Company source

Roche’s Announcement Regarding Sefaxersen (Detailed Interim Analysis Data from the Phase III IMAgINATION Study)

Chugai PharmaceuticalOriginal source

🌍Oct 26discoverynews.google.comTier 2 · Trade media

ESMO: Bristol Myers CMO touts ‘5 out of 5’ positive phase 3 trials for bispecific ADC iza-bren

Fierce PharmaOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Business WireOriginal source

🇺🇸Oct 26Industrybristolmyers2016ir.q4web.comTier 3 · Secondary coverage

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Bristol-Myers Squibb NewsOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

REG - RTW Biotech Opp. - Lycia Therapeutics prices $318 million IPO

TradingViewOriginal source

🌍Oct 26Industryavacta.comTier 1 · Company source

Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers

Avacta GroupOriginal source

🇯🇵Oct 26Industryotsuka.co.jpTier 1 · Company source

Otsuka BioVentures Begins Strategic Equity Investments

Otsuka PharmaceuticalOriginal source

🇫🇷Oct 26Researchinserm.frTier 2 · Direct publisher

Violences faites aux enfants : des traces qui durent

InsermOriginal source

🌍Oct 26discoverynews.google.comTier 2 · Trade media

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

BioSpaceOriginal source

🌍Oct 26Regulatoryeof.grTier 1 · Regulatory source

Ανάκληση παρτίδας του Ιατροτεχνολογικού προϊόντος BLAYCO Electrode tip cleaner κατηγορίας MDD Class I και του Ιατροτεχνολογικού προϊόντος DORMO-STRIP Vein strippers κατηγορίας MDD Class IIa της εταιρείας TELIC S.A.U.

EOF GreeceOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Science that competes: preparing Europe’s biotech ecosystem for global leadership

The Parliament MagazineOriginal source

🇮🇹Oct 26Researchhumanitas.itTier 2 · Direct publisher

Tumore al seno: premiata a BREASTANBUL 2026 la presentazione dello studio NEONOD2 di Humanitas

Humanitas Research HospitalOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Biotech firm Rakuten Medical wants to bring its novel ‘lightsaber’ cancer cure to the U.S.

FortuneOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

ABL Bio's Gastric Cancer Bispecific Antibody Shows 79% Tumor Shrinkage in Phase 1b; FDA Phase 3 Design Talks Complete

BigGo FinanceOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Radiopharm takes $8M advance on R&D tax credit to fund cancer trials

DealroomOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Biotech manufacturing facility opens in Brisbane

Lab + Life ScientistOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

ABL Bio reports strong gastric cancer data, sets dose and readies phase 3 - CHOSUNBIZ

ChosunbizOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

News-MedicalOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

new fda approved drugs for weight loss

BusinessWorld OnlineOriginal source

🌍Oct 26discoverynews.google.comTier 2 · Trade media

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

BioSpaceOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Ctt Pharmaceutical CEO Ryan Khouri buys $454 in shares By Investing.com

Investing.com NigeriaOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

U.S. Proposes Expanding China Investment Controls to Biotech

Caixin GlobalOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Introducing Lab Rats: A Mint series on India's biotech startups

TradingViewOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

new weight loss drug awaiting fda approval

BusinessWorld OnlineOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

The US-China biotech trade war that isn’t

Asia TimesOriginal source

🇨🇦Oct 26Researchnews.ubc.caTier 2 · Direct publisher

David Eby’s early election call backfires badly, putting Conservatives in power in B.C.

University of British ColumbiaOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Retailers Stock Performance

Yahoo FinanceOriginal source

🇯🇵Oct 26Regulatorypmda.go.jpTier 1 · Regulatory source

[SHINSA]List of Approved Regenerative Medical Products: April 2015 to July 2026

PMDA JapanOriginal source

🇯🇵Oct 26Industrychugai-pharm.co.jpTier 1 · Company source

ロシュ社によるdivarasibに関する発表について（ESMOにおけるKRAS G12C変異陽性の非小細胞肺がんに対する最新データの発表）

Chugai Pharmaceutical NewsOriginal source

🇯🇵Oct 26Industrychugai-pharm.co.jpTier 1 · Company source

Roche's Announcement Regarding divarasib (Presentation of Latest Data in KRAS G12C-Positive Non-Small Cell Lung Cancer at ESMO)

Chugai PharmaceuticalOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Israel Opens First National MDMA-Psilocybin PTSD Trial After FDA Rejection

Tech TimesOriginal source

🇺🇸Oct 26Industrythefdalawblog.comTier 3 · Secondary coverage

If You Change It, FDA Will Come: What the O.N. Diagnostics Warning Letter Means for SaMD Modifications

Hyman, Phelps & McNamara (FDA Law)Original source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist

Yahoo FinanceOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Hyundai Pharmaceutical Co., Ltd. Estimates – KRX:004310

TradingViewOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

fda making weight loss drugs harder to get

www.polskieradio.plOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

weight loss drug recently approved by fda

EMYOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Cell Biotech Co., Ltd Estimates – KRX:049960

TradingViewOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

DakLak Pharmaceutical Medical Equipment JSC Estimates – UPCOM:DBM

TradingViewOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

newly fda approved weight loss drug

EMYOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

China warnt vor Gegenmaßnahmen wegen ausgeweiteter US-Investitionsbeschränkungen für Biotech

TradingViewOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

China warns of countermeasures over expanded US investment curbs on biotech

FXStreetOriginal source

🌍Oct 26discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history

Yahoo Finance SingaporeOriginal source

Pharmaceutical industry news

Telcon Rf Pharmaceutical Wins 3.6 Billion Won Order

Biontech And Dualitybio Announce Topline Results Of Global Phase 3 Clinical Trial for Breast Cancer

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2025 to September 2026

Deeskalationsvisite – Unterstützung, Austausch und Sicherheit im Pflegealltag

BioNTech's drug modestly extended time without cancer progression vs. chemo. A few had severe or fatal lung disease.

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

New Orleans-based biotech company lured to SC as first for MUSC lab

Genmab to test drug candidate with US biotech partner

The Enzyme Nobody Watched: How Mitapivat’s Phase 3 Win Rewrites the Rules for Sickle Cell Drug Development

Hitta festivaler året om på ny karta

New lung cancer drug adds nearly six months of survival stomach cancer treatment doubles it

Synexio: the basis for shared success | Syntegon

La AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en septiembre

Kelun-Biotech's sac-TMT improves overall survival in final Phase 3 lung cancer analysis

Could new US investment curbs complicate China’s biotech licensing surge?

China warns of retaliation as US widens biotech investment restrictions

Pharmacy Students Meet Dozens of Potential Employers at Career Launch Day

ロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAgINATION試験の中間解析の詳細データ）

Roche’s Announcement Regarding Sefaxersen (Detailed Interim Analysis Data from the Phase III IMAgINATION Study)

ESMO: Bristol Myers CMO touts ‘5 out of 5’ positive phase 3 trials for bispecific ADC iza-bren

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

REG - RTW Biotech Opp. - Lycia Therapeutics prices $318 million IPO

Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers

Otsuka BioVentures Begins Strategic Equity Investments

Violences faites aux enfants : des traces qui durent

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Science that competes: preparing Europe’s biotech ecosystem for global leadership

Tumore al seno: premiata a BREASTANBUL 2026 la presentazione dello studio NEONOD2 di Humanitas

Biotech firm Rakuten Medical wants to bring its novel ‘lightsaber’ cancer cure to the U.S.

ABL Bio's Gastric Cancer Bispecific Antibody Shows 79% Tumor Shrinkage in Phase 1b; FDA Phase 3 Design Talks Complete

Radiopharm takes $8M advance on R&D tax credit to fund cancer trials

Biotech manufacturing facility opens in Brisbane

ABL Bio reports strong gastric cancer data, sets dose and readies phase 3 - CHOSUNBIZ

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

new fda approved drugs for weight loss

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

Ctt Pharmaceutical CEO Ryan Khouri buys $454 in shares By Investing.com

U.S. Proposes Expanding China Investment Controls to Biotech

Introducing Lab Rats: A Mint series on India's biotech startups

new weight loss drug awaiting fda approval

The US-China biotech trade war that isn’t

David Eby’s early election call backfires badly, putting Conservatives in power in B.C.

Pharmaceutical Retailers Stock Performance

[SHINSA]List of Approved Regenerative Medical Products: April 2015 to July 2026

ロシュ社によるdivarasibに関する発表について （ESMOにおけるKRAS G12C変異陽性の非小細胞肺がんに対する最新データの発表）

Roche's Announcement Regarding divarasib (Presentation of Latest Data in KRAS G12C-Positive Non-Small Cell Lung Cancer at ESMO)

Israel Opens First National MDMA-Psilocybin PTSD Trial After FDA Rejection

If You Change It, FDA Will Come: What the O.N. Diagnostics Warning Letter Means for SaMD Modifications

Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist

Hyundai Pharmaceutical Co., Ltd. Estimates – KRX:004310

fda making weight loss drugs harder to get

weight loss drug recently approved by fda

Cell Biotech Co., Ltd Estimates – KRX:049960

DakLak Pharmaceutical Medical Equipment JSC Estimates – UPCOM:DBM

newly fda approved weight loss drug

China warnt vor Gegenmaßnahmen wegen ausgeweiteter US-Investitionsbeschränkungen für Biotech

China warns of countermeasures over expanded US investment curbs on biotech

Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history

ロシュ社によるdivarasibに関する発表について（ESMOにおけるKRAS G12C変異陽性の非小細胞肺がんに対する最新データの発表）